drugset / Trial / NCT03696030
HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases
Phase 1
Active not recruiting
24 enrolled
City of Hope Medical Center
California Institute for Regenerative Medicine (CIRM) · collabNational Cancer Institute (NCI) · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This phase I trial studies the side effects and best dose of HER2-CAR T cells in treating patients with cancer that has spread to the brain or leptomeninges and has come back (recurrent). HER2-CAR T cells delivered into the ventricles of the brain may recognize and kill tumor cells.
Timeline
- Start
- 2018-08-31
- Primary completion
- 2027-01-24
- Completion
- 2027-01-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Axicabtagene Ciloleucel | Cell therapy | — | Other |